Jazz Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 72.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Jazz Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Jazz Pharmaceuticals is trying to complete a flat base with a 128.99 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
In terms of top and bottom line numbers, the company has posted two quarters of increasing earnings growth. Sales growth has also moved higher over the same time frame.
Jazz Pharmaceuticals holds the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the top-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
